louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04229732: Trials of Ventilation Assisted Substance Elimination Via the Lung - Ethanol (VASEL - Ethanol)
Official title: Trials of Ventilation Assisted Substance Elimination Via the Lung - Ethanol (VASEL - Ethanol)
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Alcohol Intoxication
Lead sponsor: University Health Network, Toronto
Sponsor class: OTHER
Collaborators: name: Thornhill Medical
First posted: 2020-01-18
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: This prospective, randomized control trial will use passive, isocapnic hyperventilation, applied via the ClearMateTM device (Thornhill Medical, Inc) versus controls receiving standard of care supportive management for severe alcohol intoxication to assess for enhanced ethanol elimination kinetics.


Eligibility criteria: Inclusion Criteria:

* intoxicated requiring admission to an emergency unit

Exclusion Criteria:

* Liver or renal disease

Primary outcomes:
measure: Alcohol elimination time constant
timeFrame: 6-24 hours
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT05159232: Length of Hospital Stay in Laparoscopic Transabdominal Preperitoneal Vs. Open Mesh Repair in Inguinal Hernia: A Randomised Controlled Trial
Official title: Length of Hospital Stay in Laparoscopic Transabdominal Preperitoneal Vs. Open Mesh Repair in Inguinal Hernia: A Randomised Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Inguinal Hernia
Lead sponsor: Memon Medical Institute
Sponsor class: OTHER
Collaborators: name: Khyber Teaching Hospital
First posted: 2021-12-16
Enrollment: 334
Sex: MALE
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: non-probability consecutive sampling
Primary purpose: TREATMENT

Brief summary: To compare the mean length of hospital stay in laparoscopic trans abdominal preperitoneal repair versus open mesh repair in patients undergoing inguinal hernia repair with mesh.

Detailed description: A total of 334 patients of male gender with Inguinal hernias of any side and ASA score I and II were included in the study. History of Immunosuppression, associated with other abdominal hernias and recurrent hernia were excluded. 167 patients were in Group A or laparoscopic trans abdominal preperitoneal repair group while 167 patients were in Group B or open mesh repair. Data regarding length of hospital stay from both groups was recorded by researcher himself on especially designed proforma.

Eligibility criteria: Inclusion Criteria:

* • Age 18-60 years

  * Inguinal hernias of any side as per operational definition
  * ASA score I and II

Exclusion Criteria:

* • H/o Immunosuppression

  * Associated with other abdominal hernias
  * H/o recurrent hernia

Primary outcomes:
measure: Duration of hospitals stay
timeFrame: 1-2 days
Secondary outcomes:
Other outcomes:
Locations:
city: Peshawar
country: Pakistan
facility: Khyber Teaching Hospital
state: KPK
Study officials:
affiliation: rehman Medical Institute hospital
name: Salma khan, FCPS
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04705532: Behavioral and Neurophysiological Effects of Multichannel Executive Network tDCS Combined With Preferred Music Stimulation
Official title: Behavioral and Neurophysiological Effects of Multichannel Executive Network tDCS Combined With Preferred Music Stimulation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Lead sponsor: University of Liege
Sponsor class: OTHER
First posted: 2021-01-12
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: This study aims at comparing the effects of transcranial direct current stimulation combined with music on neurophysiological outcomes in healthy participants. This study also aims to evaluate the effects of tDCS combined with music on cognition.


Eligibility criteria: Inclusion Criteria:

* healthy adults

Exclusion Criteria:

* neurological disorders
* psychiatric disorders
* contra-indication to tDCS (eg, metallic brain implant, pacemaker)
* pregnancy
* alcool abuse
* active smoker

Primary outcomes:
measure: 3-back
timeFrame: It will be measured over the course of four weeks
Secondary outcomes:
measure: Stroop
timeFrame: It will be measured over the course of four weeks
measure: EEG - alpha power
timeFrame: It will be measured over the course of four weeks
measure: EEG - beta power
timeFrame: It will be measured over the course of four weeks
Other outcomes:
Locations:
city: Liege
country: Belgium
facility: University Hospital of Liege
Study officials:
References:
Clinical trial NCT01780532: Photoacoustic Imaging (PAI) of Suspicious Breast Cancers - A Clinical Feasibility Study
Official title: Pilot Photoacoustic Imaging (PAI) of Suspicious Breast Cancers - A Clinical Feasibility Study
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Breast Cancer
Lead sponsor: Stanford University
Sponsor class: OTHER
First posted: 2013-01-31
Enrollment: 0
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: After locating the suspicious lesion/mass with standard of care mammography and/or ultrasound, a photoacoustic scan will be performed in the breast where the lesion is located. After the PA scan a biopsy will be performed, if clinically indicated (based on the mammogram and ultrasound only).


Eligibility criteria: Inclusion Criteria:

* Patients must have a breast lesion/mass found at physical examination, mammography or ultrasound (US), that has not been surgically resected
* Patients may have any of the following characteristics:

  * Taking hormones (e.g., contraceptives, hormone replacement therapy, post-cancer Tamoxifen)
  * Breast implants
  * Previous breast biopsy
  * Previous breast surgery
  * Previous breast cancer
  * High risk of breast cancer (e.g., breast cancer susceptibility gene (BRCA) mutations, other gynecologic cancer)
* Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

* Patients who have had primary surgical excision of the suspicious finding
* Pregnant or lactating women

Primary outcomes:
measure: The lesion visibility on PAI, described using a five-level scale: 1. Not visible 2. Barely visible 3. Fair (or moderately visible) 4. Visible 5. Clearly visible.
timeFrame: 6 months
Secondary outcomes:
measure: Measures of hypoxia in the lesion
timeFrame: 6 months
Other outcomes:
Locations:
Study officials:
affiliation: Stanford University
name: Sanjiv Gambhir, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04020432: Knowledge Assessment of Women About Pictograms Associated With the Danger of Medicines Taken During Pregnancy
Official title: Knowledge Assessment of Pregnant or Childbearing Age Women About Pictograms Associated With the Danger of Certain Medicines Taken During Pregnancy.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Knowledge, Attitudes, Practice
Pregnancy Related
Keywords: knowledge
medicine
pictogram
pregnant woman
childbearing age woman
Lead sponsor: Centre Hospitalier Universitaire, Amiens
Sponsor class: OTHER
Collaborators: name: Centre Hospitalier HIRSON
First posted: 2019-07-16
Enrollment: 281
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: pregnant or childbearing age women between 18 and 45 years old.

Brief summary: Women's awareness about the danger of certain medicines taken during pregnancy presents a real public health issue. To enhance awareness and information for women and healthcare professionals, new pictograms " pregnant women " appeared on medication boxes, on October 16, 2017. These new pictograms can change women's perception of self-medication during pregnancy and of the danger of taking certain medicines for the unborn development. Furthermore, the investigators can wonder if the meaning of these pictograms is well understood. Therefore, the study's primary aim is to assess the knowledge of pregnant or childbearing age women about the pictograms associated with the danger of certain medicines taken during pregnancy.


Eligibility criteria: Inclusion Criteria:

* women who agree to participate to the study
* women who understand french language (oral and written)
* pregnant women and women of childbearing age from 18 to 45 years old.

Exclusion Criteria:

* Women who have already answered the questionnaire
* women who don't want to answer the questionnaire
* women who don't understand french language
* women who are under the age of 18 or over the age of 45

Primary outcomes:
measure: Medication pictogram women knowledge measure
timeFrame: day 0
Secondary outcomes:
measure: Medication pictogram women information measure
timeFrame: day 0
Other outcomes:
Locations:
city: Amiens
country: France
facility: CHU Amiens
Study officials:
affiliation: CH Hirson
name: Alice Rousseaux
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05458232: Use of a Phosphodiesterase Type 5 Inhibitor to Improve Anabolic Resistance in Older Adults
Official title: Use of a Phosphodiesterase Type 5 Inhibitor to Improve Anabolic Resistance in Older Adults
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Sarcopenia
Lead sponsor: University of Arkansas
Sponsor class: OTHER
First posted: 2022-07-14
Enrollment: 0
Sex: MALE
Minimum age (years): 60
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Males 60-75 years who have been prescribed 5mg daily tadalafil by their physician.

Brief summary: This study will be the first demonstration of the utility and feasibility of Phosphodiesterase Type 5 inhibitor as an effective pharmacological therapy for improving anabolic resistant states.


Eligibility criteria: Inclusion Criteria:

* Ages 60-75 yrs
* Recently prescribed 5mg of tadalafil daily for clinical purposes

Exclusion Criteria:

* History of diabetes
* history of hypotension including orthostatic hypotension
* History of malignancy or chemo/radiation therapy in the 6 months prior to enrollment
* History of short gut syndrome, gastrointestinal bypass/reduction surgery (Lap band, gastric sleeve, etc.)
* Subjects who cannot refrain from using protein or amino acid supplements for 7 days prior to Visit 2 and 3.
* Alcohol consumption of ≥ 5 units/servings per day
* Concomitant use of

  * oral or injectable corticosteroids
  * testosterone, insulin like growth factor-1, or similar anabolic agent
  * riociguat (Adempas)
  * nitroglycerin
  * isosorbide dinitrate (Isordil)
  * isosorbide mononitrate (Imdur, Monoket)
  * doxazosin (Cardura)
  * prazosin (Minipress)
  * terazosin (Hytrin)
* Any other disease or condition that would place the subject at increased risk of harm if they were to participate, at the discretion of the study physician

Primary outcomes:
measure: Change in maximal voluntary contraction of lower leg.
timeFrame: 14 days
Secondary outcomes:
measure: Change in muscle Fatigue
timeFrame: 14 days
Other outcomes:
Locations:
city: Little Rock
country: United States
facility: University of Arkansas for Medical Sciences
state: Arkansas
Study officials:
References:
citation: Rosenberg IH. Sarcopenia: origins and clinical relevance. J Nutr. 1997 May;127(5 Suppl):990S-991S. doi: 10.1093/jn/127.5.990S.
Clinical trial NCT00713232: The Construction of a Chinese Picture Naming Test and Its Preliminary Normative Data
Official title: The Construction of a Chinese Picture Naming Test and Its Preliminary Normative Data
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Normality
Keywords: naming test
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2008-07-11
Enrollment: 522
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 1. university student
2. normal subjects

Brief summary: We will construct a Chinese Picture Naming test which include 60 items with various word frequency and familiarity and is arranged by their familiarity in daily life.

Then we will collect the normative data for this test using normal subjects of various age and educational level.

Detailed description: In this study, we will first construct a Chinese Picture Naming Testing following the format of Boston Naming test. We will use the original 60 items from BNT and also choose another 100 items of objects with various frequency using the word frequency data from the Linguistic Corpus of the Academia Sinica. Colored pictures will be constructed accordingly. University students will be recruited to name the pictures and to judge the familiarity and image agreement for these pictures. Then, we will choose 60 pictures of according to the principles of 1. high image agreement 2. high naming agreement 3. including items of various familiarity and word frequency 4. double or triple phoneme words 5. including the original BNT items as possible. The 60 pictures will be arranged by their familiarity to construct the Chinese Picture Naming Test.

Then, we will recruit normal subjects of various age group and educational level to to the Naming test and to construct the preliminary norm.

Eligibility criteria: Inclusion Criteria:

* living in Taiwan for more than 5 years fluent in Chinese

Exclusion Criteria:

* previous neurological, psychiatric or speech language disorders

Primary outcomes:
measure: naming accuracy
timeFrame: 10 minutes
Secondary outcomes:
measure: naming agreement
timeFrame: 10 min
measure: image agreement
timeFrame: 10 min
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: National Taiwan University Hospital
Study officials:
affiliation: National Taiwan University Hospital
name: Lu Lu, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT06233032: Could Ephedrine Replace Dexmedetomidine Fordexmedetomidine Prevention of Shivering in Women Undergoing Cesarean Section Under Spinal Anaesthesia
Official title: Could Ephedrine Replace Dexmedetomidine for Prevention of Shivering in Women Undergoing Cesarean Section Under Spinal Anaesthesia
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Prevention of Shivering With Spinal Anaesthesia
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2024-01-31
Enrollment: 200
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Could ephedrine replace dexamedetomidine for prevention of shivering in women undergoing Cesarean section Under spinal anaesthesia

Detailed description: Shivering, rhythmic oscillatory movement of upper limbs, neck and jaw, is common during regional anesthesia with an incidence up to 56.7% of patients. Perioperative shivering is a commonly observed clinical problem well known to anesthesiologists caring for women undergoing a Cesarean delivery (CD). The median incidence of shivering in parturients having labour epidural analgesia or CD with epidural or spinal anesthesia has been estimated to be 52%.1 Severe shivering causes physiologic stress, interferes with patient monitors, and decreases the comfort and overall satisfaction of women during childbirth. Ephedrine well-known sympathomimetic agent, has been used to treat hypotension during regional anesthesia. It has antiemetic effect for short-term . Ephedrine maintained hemodynamics and minimized decrease of the core temperature when given by an intravenous infusion during spine surgery under general anesthesia . Dexmedetomidine, a selective a-2 agonist, was introduced in clinical practice in the United States in 1999. It is approved by Health Canada as a short-term sedative for mechanically ventilated adult patients in the intensive care unit and sedation of non-intubated patients prior to and/or during surgical procedures. It has since been approved and is widely used in pediatric populations and for procedural sedation of non-intubated patients.9 Nevertheless, the clinical use of dexmedetomidine has expanded to various off-label uses. In obstetrical anesthesia, it has been used as part of multi-modal intravenous labour and post-CD analgesia,10-13 as a neuraxial adjunct in the epidural space for labour,14 and intrathecally for shivering prevention during CD

Eligibility criteria: Inclusion Criteria:

* Adult female from 18 to 35 yrs
* uncomplicated pregnancy for elective cesarean delivery

Exclusion Criteria:

* patient refusal
* allergy to the drug
* contraindications of spinal anaesthesia
* patients with DM or thyroid disorders

Primary outcomes:
measure: Prevention of shivering during spinal anaesthesia in cesarean delivery .Intensity of shivering assessed using five point scale
timeFrame: 45min
Secondary outcomes:
Other outcomes:
Locations:
city: Assiut
country: Egypt
facility: Assiut university
Study officials:
References:
Clinical trial NCT02608632: HFS-guided Renal Ablation for Improving Outcome of Renal Denervation Procedure
Official title: High Frequency Guided Renal Artery Denervation for Improving Outcome of Renal Ablation Procedure
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Hypertension
Keywords: Renal denervation
Ablation
Lead sponsor: Meshalkin Research Institute of Pathology of Circulation
Sponsor class: NETWORK
First posted: 2015-11-20
Enrollment: 170
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To increase the number of responders using HFS-guided renal artery denervation (RDN) in patients with resistant and moderate resistant hypertension


Eligibility criteria: Inclusion Criteria:

* Office-based systolic blood pressure of ≥140/90 mm Hg and \<160/100 mm Hg (moderate resistant hypertension) or ≥160/100 mm Hg (severe resistant hypertension), despite treatment with 3 antihypertensive drugs (including a diuretic).
* A glomerular filtration rate ≥45 mL/min/1⋅73 m2, with modification of diet using a renal disease formula.

Exclusion Criteria:

* Secondary causes of hypertension
* Severe renal artery stenosis or dual renal arteries
* Congestive heart failure
* Left ventricular ejection fraction \<35%
* Previous renal artery stenting or angioplasty
* Type 1 diabetes mellitus

Primary outcomes:
measure: number of responders to renal denervation procedure
timeFrame: 12 month
Secondary outcomes:
measure: complications rate
timeFrame: 12 month
measure: cross-over rate
timeFrame: 12 month
Other outcomes:
Locations:
city: Krasnoyarsk
country: Russian Federation
facility: Federal Center of Cardiovascular surgery
city: Krasnoyarsk
country: Russian Federation
facility: Regional Hospital
city: Moscow
country: Russian Federation
facility: Federal Center of Prophylactic Medicine
Study officials:
References:
Clinical trial NCT06262932: Effectiveness of Repeated Amiodarone Dosing Regimen Versus Standard Dosing Regimen in Atrial Fibrillation Patient With Rapid Ventricular Response
Official title: Effectiveness of Repeated Amiodarone Dosing Regimen Versus Standard Dosing Regimen in Atrial Fibrillation Patient With Rapid Ventricular Response
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Atrial Fibrillation
Lead sponsor: Police General Hospital, Thailand
Sponsor class: OTHER
First posted: 2024-02-16
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The goal of this clinical trial is to compare in atrial fibrillation patient with rapid ventricular response. The main question it aims to answer are Effectiveness of Repeated Amiodarone dosing regimen versus standard dosing regimen in Atrial fibrillation patient with rapid ventricular response Participants will receive Amiodarone iv treatment with different regimen

* Repeated dosing regimen
* Standard dosing regimen


Eligibility criteria: Inclusion Criteria:

* Age above 18 years old
* Atrial fibrillation with rapid ventricular response patient (ventricular rate \> 110)

Exclusion Criteria:

* Baseline EKG Corrected QT interval (QTc) \< 500 msec
* History of pulmonary fibrosis
* History of Cirrhosis
* Cardiac Index \<2.2 L/min/m2 or Cardiogenic shock
* Unstable arrhythmia
* Receive amiodarone within 3 months prior to present illness
* Pregnancy
* Amiodarone or Iodine allergy

Primary outcomes:
measure: Heart rate
timeFrame: 6-hours after receiving amiodarone bolus
Secondary outcomes:
measure: Normal sinus rhythm at 24 hours
timeFrame: 24-hours after receiving amiodarone bolus
measure: Heart rate
timeFrame: 24-hours after receiving amiodarone bolus
measure: Major adverse cardiovascular events
timeFrame: 30 days after receiving amiodarone bolus
measure: Phlebitis
timeFrame: 24-hours after receiving amiodarone bolus
measure: Changed in heart rate
timeFrame: 24-hours after receiving amiodarone bolus
Other outcomes:
Locations:
city: Bangkok
country: Thailand
facility: Police general hospital
Study officials:
References: